{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:37:03Z","timestamp":1774485423190,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korean Society of Hematology","award":["ICKSH-2024-02"],"award-info":[{"award-number":["ICKSH-2024-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The prognosis of a plasma cell neoplasm (PCN) varies depending on the presence of genetic abnormalities. However, detecting sensitive genetic mutations poses challenges due to the heterogeneous nature of the cell population in bone marrow aspiration. The established gold standard for cell sorting is fluorescence-activated cell sorting (FACS), which is associated with lengthy processing times, substantial cell quantities, and expensive equipment. Magnetic-activated cell sorting (MACS) can be performed without the need for FACS equipment and allows for rapid sorting of many cells, making it a practical alternative. Our objective is to conduct a comparative analysis of these two sorting techniques to assess whether MACS can viably replace FACS in clinical applications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Plasma cell purity, fluorescence in situ hybridization (FISH), and next-generation sequencing analyses were performed on FACS- and MACS-sorted bone marrow samples from 31 PCN patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The MACS-sorted samples yielded a higher percentage of plasma cells than FACS-sorted samples under microscopy (<jats:italic>p<\/jats:italic>\u2009=\u20090.0156) and flow cytometry (<jats:italic>p<\/jats:italic>\u2009=\u20090.0313). FISH performed by two methods in 10 samples showed the same results, and the proportion of abnormal cells was significantly higher in MACS than in FACS (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Wilcoxon matched-pairs signed rank test analysis showed that the median of differences of variant allele frequency (VAF) of two methods (VAF of MACS minus VAF of FACS) in the <jats:italic>DNMT3A<\/jats:italic>, <jats:italic>TET2<\/jats:italic>, and <jats:italic>ASXL1<\/jats:italic> (DTA) group was \u2212\u20090.006555 (<jats:italic>p<\/jats:italic>\u2009=\u20090.0020), while that in the non-DTA group was 0.002805 (<jats:italic>p<\/jats:italic>\u2009=\u20090.0019). Ten copy number variants (CNVs) were found in both FACS- and MACS-sorted samples, eight were identified only in MACS-sorted samples, and one was detected only in FACS-sorted samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study demonstrates that MACS is a viable alternative for plasma cell sorting in bone marrow samples of patients with PCN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12935-025-03647-8","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:04:00Z","timestamp":1737108240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-6926","authenticated-orcid":false,"given":"Yu Jeong","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4812-3574","authenticated-orcid":false,"given":"Jaeguk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4888-1356","authenticated-orcid":false,"given":"Yehyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1501-3923","authenticated-orcid":false,"given":"Saeam","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1047-1415","authenticated-orcid":false,"given":"Seung-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-2989","authenticated-orcid":false,"given":"Jong Rak","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"3647_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"3647_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3647_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9:102.","journal-title":"Blood Cancer J"},{"key":"3647_CR4","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41375-018-0030-3","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32:1811\u20135.","journal-title":"Leukemia"},{"key":"3647_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12185-010-0651-4","volume":"92","author":"J Cumova","year":"2010","unstructured":"Cumova J, Kovarova L, Potacova A, Buresova I, Kryukov F, Penka M, et al. Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. Int J Hematol. 2010;92:314\u20139.","journal-title":"Int J Hematol"},{"key":"3647_CR6","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"3647_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41598-018-36698-1","volume":"9","author":"BA Sutermaster","year":"2019","unstructured":"Sutermaster BA, Darling EM. Considerations for high-yield, high-throughput cell enrichment: fluorescence versus magnetic sorting. Sci Rep. 2019;9:227.","journal-title":"Sci Rep"},{"key":"3647_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/cge.14236","volume":"103","author":"H Kim","year":"2023","unstructured":"Kim H, Shim Y, Lee TG, Won D, Choi JR, Shin S, et al. Copy-number analysis by base-level normalization: an intuitive visualization tool for evaluating copy number variations. Clin Genet. 2023;103:35\u201344.","journal-title":"Clin Genet"},{"key":"3647_CR9","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.7150\/jca.76719","volume":"13","author":"HW Kook","year":"2022","unstructured":"Kook HW, Kim JJ, Park MR, Jang JE, Min YH, Lee ST, et al. Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia. J Cancer. 2022;13:3326\u201332.","journal-title":"J Cancer"},{"key":"3647_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4\u201323.","journal-title":"J Mol Diagn"},{"key":"3647_CR11","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364\u20137.","journal-title":"Haematologica"},{"key":"3647_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03647-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:04:03Z","timestamp":1737108243000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03647-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03647-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempted from institutional review board (IRB) review by the IRB of Severance Hospital, Seoul, Korea (4-2024-0690) because it uses residual specimens.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The IRB waived the requirement for informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}